Evidence map›Paper›PMID 38075247›Full record

ArticleMolecular therapy oncolytics2023

Kinetic analysis of oncolytic OrfV-induced innate and adaptive immune responses in a murine model of late-stage ovarian cancer.

Jessica A Minott, Jacob P van Vloten, Jake G E Yates, Lisa A Santry, Kathy Matuszewska, Madison Pereira, Melanie M Goens, Alicia M Viloria-Petit, Geoffrey A Wood, Khalil Karimi and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy oncolytics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Jessica A MinottDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Jacob P van VlotenDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Jake G E YatesDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Lisa A SantryDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Kathy MatuszewskaDepartment of Biomedical Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada.
Madison PereiraDepartment of Biomedical Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada.
Melanie M GoensDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Alicia M Viloria-PetitDepartment of Biomedical Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada.
Geoffrey A WoodDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Khalil KarimiDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
James J PetrikDepartment of Biomedical Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada.
Byram W BridleDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Sarah K WoottonDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
University of Guelph · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapies revive host immune responses against tumors by stimulating innate and adaptive immune effector cells with antitumor functions. Thus, detailed studies of immunological cell phenotypes and functions within the tumor microenvironment (TME) following immunotherapy treatments is critical to identifying the determinants of therapeutic success, optimizing treatment regimens, and driving curative outcomes. Oncolytic viruses such as Orf virus (OrfV) are multifunctional biologics that preferentially infect and kill cancer cells while simultaneously causing inflammation that drives anticancer immune responses. Here, we describe the immunological impact of OrfV on the ascites TME in a preclinical model of advanced-stage epithelial ovarian cancer. OrfV promoted the infiltration of several immune effector cells with increased expression of activation markers and effector cytokines into the ascites TME, which correlated with reduced ascites tumor burden and improved survival. The kinetics of the immune response and change in tumor burden following OrfV therapy revealed an optimal re-administration time to sustain antitumor immunity, further extending survival. The data presented highlight the importance of investigating immune response kinetics following immunotherapy and demonstrate that detailed kinetic profiling of immune responses can reveal novel insights into mechanisms of action that can guide the development of more effective therapies.

Indexed as

antitumor immunityascitesimmune response kineticsoncolytic virusovarian cancertumor microenvironmentviral immunotherapy

Identifiers

PMID38075247
PMCPMC10701082
OpenAlexW4388570838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.